Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$159.69 USD
+0.16 (0.10%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $159.69 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$159.69 USD
+0.16 (0.10%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $159.69 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth F Momentum D VGM
Zacks News
Upcoming Consumer Earnings Reports to Watch: JNJ, F, SBUX
by Ryan McQueeney
Fourth-quarter earnings season is finally underway, and investors are already getting excited about the upcoming reports from market-moving tech companies like Netflix (NFLX). Make sure to keep an eye on these companies as they prepare to report during the week of January 22.
Will J&J's (JNJ) Pharma Segment Pull Up its Q4 Earnings?
by Zacks Equity Research
J&J's (JNJ) pharma segment sales growth accelerated in the third quarter and we are likely to see, a continuation of the positive trend in the fourth quarter.
The Zacks Analyst Blog Highlights: Johnson & Johnson, AbbVie, Amgen, Novo-Nordisk and Zoetis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, AbbVie, Amgen, Novo-Nordisk and Zoetis
Can These 4 Large-Cap Drug Stocks Deliver an Encore in '18?
by Zacks Equity Research
We present four large cap drug companies, which are expected to repeat their last year's industry beating performance in 2018.
Amgen Gets FDA Nod to Add ENDEAVOR Data on Kyprolis Label
by Zacks Equity Research
Amgen (AMGN) gets an earlier-than-expected approval to include ENDEAVOR study OS data on Kyprolis label.
Market at New Highs: Mega Cap ETFs & Stocks On A Roll
by Sweta Killa
Inside mega cap ETFs & stocks hitting all-time highs with the skyrocketing market.
J&J (JNJ) Hits New 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Promising data from several pivotal studies and a rapid pipeline progress contribute to a rally in Johnson & Johnson's (JNJ) shares.
J&J (JNJ) to Set Pharma Q4 Earnings in Motion: What's Up?
by Zacks Equity Research
The positive trend seen in J&J's (JNJ) pharma segment sales in Q3 is likely to continue in Q4. Strong pharma performance and contribution from acquisitions should support the top line.
Abbott's (ABT) Diabetes Care Unit Strong on FreeStyle Libre
by Zacks Equity Research
Abbott (ABT) forges ahead with initiatives to boost diabetes care. The latest CMS recognition will widen customer base for FreeStyle Libre glucose monitoring system.
After a Solid Start, What Awaits Dow ETF in Q4 Earnings?
by Sweta Killa
How will Dow ETF perform in Q4 Earnings?
Big Pharma CEOs Speak About Impact of Tax Reform on M&A
by Zacks Equity Research
This week, senior executives of some large drug companies discussed the impact of tax reform on mergers and acquisition and their plans to use the excess cash at the JP Morgan HealthCare conference.
Pfizer to Stall R&D for Alzheimer's/Parkinson's, Cut Jobs
by Zacks Equity Research
Pfizer (PFE) will reportedly end R&D efforts in Alzheimer's and Parkinson's disease areas, which will result in about 300 job cuts.
Celsion's Phase I/II Cancer Study Initiation Gets FDA Nod
by Zacks Equity Research
Celsion's (CLSN) plan for phase I/II study to evaluate DNA-based immunotherapy, GEN-1, in ovarian cancer gets FDA approval and clearance for initiation.
Will J&J (JNJ) Continue to Tread Growth Path This Year?
by Zacks Equity Research
Johnson & Johnson's (JNJ) stock was up last year. The positive trend is likely to continue this year as well.
Can AbbVie (ABBV) Stock Keep the Momentum Alive in 2018?
by Zacks Equity Research
AbbVie Inc. (ABBV) shares are expected to be northbound in 2018, carrying on the momentum achieved last year.
Portola's (PTLA) AndexXa BLA Review Period Extended by FDA
by Zacks Equity Research
The FDA extends the review period of Portola's (PTLA) biologics license application for AndexXa by 90 days. Its response is now deferred to May 4, 2018 instead of the earlier Feb 3 deadline.
Biogen's Alzheimer's Drug Misses Goal in Interim Analysis
by Zacks Equity Research
Biogen (BIIB) Alzheimer's candidate, BAN2401, failed to meet the criteria for success based on a 12 months interim analysis as the primary endpoint in a mid-stage trial.
Minerva Initiates Phase III Study on Schizophrenia Candidate
by Zacks Equity Research
Minerva Neurosciences (NERV) initiates a phase III study to evaluate MIN-101 as monotherapy to treat negative symptoms in schizophrenia patients.
Achillion's Renal Disease Candidate Gets Orphan Drug Status
by Zacks Equity Research
Achillion Pharmaceuticals' (ACHN) factor D inhibitor, ACH-4471, gets orphan drug designation for treating C3G, a renal disease.
Allergan's Vraylar Positive for Bipolar Disease in Phase III
by Zacks Equity Research
Allergan (AGN) releases positive top-line results from a phase III study on Vraylar for treatment of bipolar I depression. The trial meets its primary endpoints with significant progress in patients.
3 Low-Volatility ETFs for Your Portfolio
by Zacks Equity Research
Low-volatility ETFs might seem attractive to investors, as GOP Senate majority slims.
Pfizer's Arthritis Drug Gets FDA Nod for Label Expansion
by Zacks Equity Research
The FDA approves label expansion of Pfizer's (PFE) JAK inhibitor Xeljanz for two doses on an impressive data from two phase III studies.
The Zacks Analyst Blog Highlights: Microsoft, Johnson & Johnson, ExxonMobil, American Airlines and Honda
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, Johnson & Johnson, ExxonMobil, American Airlines and Honda
Pfizer's Second Biosimilar of Remicade Receives FDA Approval
by Zacks Equity Research
The FDA approves Ixifi, Pfizer's (PFE) second biosimilar version of Johnson & Johnson's rheumatoid arthritis drug, Remicade. Ixifi receives the nod for all approved indications of Remicade.
Top Analyst Reports for Microsoft, Johnson & Johnson & ExxonMobil
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Johnson & Johnson (JNJ) and ExxonMobil (XOM).